Host immunity modulates the efficacy of microbiota transplantation for treatment of Clostridioides difficile infection.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33531483.
- Also identified by DOI 10.1038/s41467-020-20793-x and PMC identifier 7854624.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Fecal microbiota transplantation (FMT) is a successful therapeutic strategy for treating recurrent Clostridioides difficile infection. Despite remarkable efficacy, implementation of FMT therapy is limited and the mechanism of action remains poorly understood. Here, we demonstrate a critical role for the immune system in supporting FMT using a murine C. difficile infection system. Following FMT, Rag1 heterozygote mice resolve C. difficile while littermate Rag1<sup>-/-</sup> mice fail to clear the infection. Targeted ablation of adaptive immune cell subsets reveal a necessary role for CD4<sup>+</sup> Foxp3<sup>+</sup> T-regulatory cells, but not B cells or CD8<sup>+</sup> T cells, in FMT-mediated resolution of C. difficile infection. FMT non-responsive mice exhibit exacerbated inflammation, impaired engraftment of the FMT bacterial community and failed restoration of commensal bacteria-derived secondary bile acid metabolites in the large intestine. These data demonstrate that the host's inflammatory immune status can limit the efficacy of microbiota-based therapeutics to treat C. difficile infection.
Medical subject headings
- Clostridioides difficile